Back to search

Article

The Alzheimer’s therapeutic Lecanemab induces an amyloid-clearing program in microglia

2025-07-27

Abstract excerpt

Controversies over anti-amyloid immunotherapies underscore the need to elucidate their mechanisms of action. Here we demonstrate that Lecanemab, a leading anti-Aβ antibody, mediates amyloid clearance by triggering effector functions in the microglia. Using a human microglia xenograft model, we show that Lecanemab significantly reduces Aβ pathology and associated neuritic damage, while neither Fc-inactivated Lecane...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cc8616ac-d240-5c2d-8c0e-674d28a7f0af
DOI
10.1101/2025.07.24.666347
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The Alzheimer’s therapeutic Lecanemab induces an amyloid-clearing program in microgliaDOI 10.1101/2025.07.24.666347
Select a neighboring publication to make it the new centre.